1. Bile Acids Improve Psoriasiform Dermatitis through Inhibition of IL-17A Expression and CCL20-CCR6-Mediated Trafficking of T Cells
- Author
-
Xuesong Wu, Chun-Yi Wu, Samuel T Hwang, Timothy Law, Zhenrui Shi, Joshua M. Farber, William Liakos, Guiyan Yang, Yu-Jui Yvonne Wan, Daisuke Yamada, Mindy Huynh, and Satya P. Singh
- Subjects
Receptors, CCR6 ,Lithocholic acid ,education ,Clinical Sciences ,Oncology and Carcinogenesis ,Eczema ,Dermatology ,Pharmacology ,Biochemistry ,Jurkat cells ,Interleukin-23 ,Article ,Oral and gastrointestinal ,Bile Acids and Salts ,chemistry.chemical_compound ,Mice ,Receptors ,medicine ,Animals ,Humans ,Psoriasis ,Gamma delta T cell ,Receptor ,Molecular Biology ,Chemokine CCL20 ,Chemistry ,Liver Disease ,Dermatology & Venereal Diseases ,Deoxycholic acid ,Interleukin-17 ,Cell Biology ,G protein-coupled bile acid receptor ,medicine.anatomical_structure ,Farnesoid X receptor ,CCR6 ,Digestive Diseases ,Ex vivo - Abstract
Bile acids (BAs), produced in the liver and further transformed in the gut, are cholesterol-derived molecules involved in essential physiological processes. Recent studies suggest that BAs regulate T helper 17 cell function, but the underlying mechanism of this action and their therapeutic value in disease models remains unclear. Using an IL-23 minicircle DNA-based murine model of psoriasiform dermatitis, we showed that oral administration of secondary BAs, including lithocholic acid (LCA), deoxycholic acid, and 3-oxoLCA, significantly improved psoriasiform dermatitis without inducing apparent hepatotoxicity. Of the BAs tested, LCA possessed the greatest potency in treating psoriasiform dermatitis. Intravenous administration of LCA at a much lower dosage (compared with oral treatment) showed a comparable antipsoriatic effect and markedly suppressed the IL-17A response. Exvivo experiments revealed that LCA reduced IL-17A production in IL-23-stimulated murine T cells in the absence of BA receptors TGR5 or FXR. Strikingly, BAs inhibited CCL20 expression in keratinocytes, which led to reduced migration of CCR6-expressing Jurkat cells cultured in the conditioned medium of stimulated keratinocytes. Thus, BAs improve psoriasiform dermatitis with minimal toxicity via direct inhibition of IL-17A production and blockade of CCL20-mediated trafficking, supporting the potential use of BAs in psoriasis.
- Published
- 2022